Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00083252 · ClinicalTrials.gov registry record · Phase 2
Study of Talabostat and Cisplatin in Advanced Melanoma
A Phase 2 study of Melanoma and Skin Cancer, sponsored by Point Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 13
- Study locations
NCT00083252 is a Phase 2 study of Melanoma and Skin Cancer that has completed, run by Point Therapeutics. The trial reports 13 study locations across 11 states.
The verdict
NCT00083252, a Phase 2 study of Melanoma and Skin Cancer, has completed, sponsored by Point Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 13
- Study locations
Study Summary
The purpose of this study is to assess the antitumor activity and safety of the combination of talabostat and cisplatin in patients with metastatic melanoma.
Conditions Studied
Interventions
- DRUG cisplatin
- DRUG talabostat (PT-100) tablets
Study Locations (13)
New York
- NYU School of Medicine - New York
- Fifth Avenue Medical Healthcare - New York
Texas
- Mary Crowley Medical Research Center - Dallas
- Tyler Cancer Center - Tyler
Arkansas
- University of Arkansas Medical Sciences - Little Rock
California
- Cancer Institute Medical Group, Inc. - Santa Monica
Colorado
- University of Colorado Health Sciences Center - Aurora
Florida
- Cancer Center of Florida - Ocoee
Indiana
- Indiana Hematology Oncology Consultants - Indianapolis
New Mexico
- New Mexico Cancer Center Alliance - Albuquerque
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00083252
The ClinicalTrials.gov registry entry for NCT00083252 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Point Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Melanoma appearing as the primary indexed condition, and to 2 interventions - of which cisplatin is the first listed.
NCT00083252 reports 13 study locations spanning 11 distinct geographic areas - top geographies include New York, Texas, Arkansas.
Frequently Asked Questions
What is clinical trial NCT00083252 about?
NCT00083252 is a clinical study titled "Study of Talabostat and Cisplatin in Advanced Melanoma". The purpose of this study is to assess the antitumor activity and safety of the combination of talabostat and cisplatin in patients with metastatic melanoma.
What is the current status of trial NCT00083252?
This trial is currently completed. It is a Phase 2 study.
What conditions does trial NCT00083252 study?
This clinical trial studies the following conditions: Melanoma, Skin Cancer.
What interventions are being tested in trial NCT00083252?
The interventions under investigation include: cisplatin (DRUG), talabostat (PT-100) tablets (DRUG).
Who is sponsoring clinical trial NCT00083252?
This trial is sponsored by Point Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00083252 being conducted?
This trial has 13 study locations across Arkansas, California, Colorado, Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
RECRUITING · Phase 2
-
Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma
RECRUITING · Phase 2
-
A Study of IBI363 in Subjects with Advanced Solid Malignancies
RECRUITING · Phase 2
-
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
RECRUITING · Phase 2
-
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.